A child-friendly formulation of the antiretroviral drug dolutegravir was first included in the country’s HIV treatment guidelines in 2023. New estimates suggest that most children aged one to four living with HIV have now been switched to the drug, reports Elri Voigt.
Massive gains have been made in reducing new HIV infections and deaths in children. Yet, many of the statistics for children still look worse than those for adults. Elri Voigt asked experts why this is the case and what factors prevent children living with HIV from starting and staying on the treatment that can keep them healthy.
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
Research led by Professor Adrie Bekker is paving the way for an important HIV medicine to be made available to neonates in a way that is both safe and much more convenient than previous options. Biénne Huisman met with the passionate clinician-scientist at her office in Cape Town.
